[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31670":3,"doc-seo-31670":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31670,34359740700684,"Finn","https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487",7,"Healthcare","OP0095 Deucravacitinib Efficacy and Safety Up to Week 52 From POETYK PSA-2","Deucravacitinib, an oral selective allosteric TYK2 inhibitor, is evaluated for active psoriatic arthritis (PsA) in the multicenter randomized double-blind phase 3 POETYK PsA-2 study. Adult patients naive to biologic DMARDs, TNF inhibitors, or with up to two prior TNFi failures/intolerance were eligible. The trial used ACR20 at week 16 as the primary endpoint and included key secondary measures of musculoskeletal, skin, disease activity, and quality of life, with hierarchical testing and a placebo-to-deucravacitinib switch through week 52; safety was assessed up to week 52.","cbCaii0QYDwUAVzZ","https://ap.wps.com/l/cbCaii0QYDwUAVzZ","pdf",288596,1,2,"English","en","# Background and Objectives\n## Methods\n## Results and Safety","[{\"question\":\"What is the primary endpoint of the POETYK PsA-2 study?\",\"answer\":\"The primary endpoint is ACR20 response at week 16.\"},{\"question\":\"Which patients were included in this trial?\",\"answer\":\"Adults with active PsA meeting CASPAR criteria, with active arthritis, a documented plaque psoriasis history, and hsCRP ≥ 3 mg/L at screening were included, including those naive to biologic DMARDs/TNFi or with up to two prior TNFi failures or intolerance.\"},{\"question\":\"How were treatments assigned and handled after week 16?\",\"answer\":\"Patients were randomized 3:3:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily through week 16; from weeks 16 to 52, deucravacitinib/apremilast continued while placebo patients switched to deucravacitinib, and safety was evaluated through week 52.\"}]",1779915615,5,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":83,"head_meta":85,"extra_data":87,"updated_unix":25},105,"op0095-deucravacitinib-efficacy-and-safety-up-to-week-52-from-poetyk-psa-2","",{"@graph":34,"@context":82},[35,51,65],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,45,48],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":20},"https://docshare.wps.com/document/","Document",{"item":46,"name":12,"@type":41,"position":47},"https://docshare.wps.com/document/healthcare/",3,{"item":49,"name":13,"@type":41,"position":50},"https://docshare.wps.com/document/op0095-deucravacitinib-efficacy-and-safety-up-to-week-52-from-poetyk-psa-2/31670/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":59,"encodingFormat":58,"isAccessibleForFree":60,"interactionStatistic":61},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":39,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-05-27",true,{"@type":62,"interactionType":63,"userInteractionCount":4},"InteractionCounter",{"@type":64},"ViewAction",{"@type":66,"mainEntity":67},"FAQPage",[68,74,78],{"name":69,"@type":70,"acceptedAnswer":71},"What is the primary endpoint of the POETYK PsA-2 study?","Question",{"text":72,"@type":73},"The primary endpoint is ACR20 response at week 16.","Answer",{"name":75,"@type":70,"acceptedAnswer":76},"Which patients were included in this trial?",{"text":77,"@type":73},"Adults with active PsA meeting CASPAR criteria, with active arthritis, a documented plaque psoriasis history, and hsCRP ≥ 3 mg/L at screening were included, including those naive to biologic DMARDs/TNFi or with up to two prior TNFi failures or intolerance.",{"name":79,"@type":70,"acceptedAnswer":80},"How were treatments assigned and handled after week 16?",{"text":81,"@type":73},"Patients were randomized 3:3:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily through week 16; from weeks 16 to 52, deucravacitinib/apremilast continued while placebo patients switched to deucravacitinib, and safety was evaluated through week 52.","https://schema.org",{"og:url":49,"og:type":84,"og:title":13,"og:site_name":56,"og:description":14},"article",{"robots":86,"canonical":49},"index,follow",{"doc_id":7,"site_id":30}]